Pulse Biosciences (NASDAQ:PLSE) Trading 5.3% Higher – Here’s Why

Pulse Biosciences, Inc (NASDAQ:PLSE)’s stock price traded up 5.3% on Wednesday . The stock traded as high as $51.07 and last traded at $51.3950. Approximately 121,724 shares traded hands during trading, a decline of 66% from the average session volume of 362,152 shares. The stock had previously closed at $48.79.

Analysts Set New Price Targets

A number of research analysts have issued reports on PLSE shares. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Needham & Company LLC started coverage on Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Canaccord Genuity Group lifted their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Trading Up 15.9%

The business has a fifty day moving average of $38.88 and a 200-day moving average of $28.41. The firm has a market cap of $3.91 billion, a PE ratio of -47.83 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. On average, equities analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Buying and Selling

In other news, COO Liane Teplitsky purchased 1,036 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the transaction, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at approximately $49,966.28. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have acquired 4,095 shares of company stock valued at $199,931. 74.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Pulse Biosciences during the 2nd quarter valued at about $28,000. Alliancebernstein L.P. grew its holdings in shares of Pulse Biosciences by 6.7% during the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.